Loading...
Management of malignant fungating wounds with a bioactive microfibre gelling technology dressing: an evaluation
Pramod, Susy
Pramod, Susy
Citations
Altmetric:
Abstract
In this article, we aim to raise awareness of some of the clinical concerns surrounding the management of oncology wounds, particularly malignant fungating wounds. We will also provide practical wound management recommendations for healthcare professionals to consider when managing this wound type. We aim to assess the potential of a 100% chitosan with bioactive microfibre gelling (BMG™) dressing (MaxioCel®), to support wound management and work in partnership with industry to deliver clinical education on the management of oncology wounds, including malignant fungating wounds. Method: A case study series was undertaken over four weeks, using the chitosan BMG dressing. Results: We recruited 10 patients during the study. The chitosan BMG dressing facilitated a significant improvement in wound tissue type, exudate levels, and periwound skin, as well as reduced malodour. A reduction in patient-reported pain levels was also noted throughout the evaluation process. Conclusion: The introduction of BMG fibre technology demonstrated good outcomes in this patient group, in a short period of time. Importantly for this patient group, the BMG dressing was able to remain in situ during radiotherapy treatment, allowing uninterrupted management of the wounds.
Authors
Affiliation
Description
Date
2023-11
Publisher
Collections
Keywords
Type
Article
Citation
Pramod, S. and Rice, S. (2023) ‘Management of malignant fungating wounds with a bioactive microfibre gelling technology dressing: an evaluation’, Wounds UK, 19(4), pp. 68–77.